Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Gait assessment · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Foot alignmentPirani score. Scale from: 0 to 6. A lower score indicates better alignment · participants with CTEV at initial presentation Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 1 study · 38 participants | Low |
Intervention NR Adverse events · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Function ‐ · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Foot alignment Pirani score. A lower score indicates better alignment. Scale from: 0 to 6. · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Intervention NR Gait assessment · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 1 study · 5 participants | Low |
Intervention NR Gait assessment · participants with CTEV at initial presentation Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with CTEV at initial presentation Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 2 studies · 2 participants | Ungraded |
Intervention NR Adverse events · participants with CTEV at initial presentation Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 1 study · 25 participants | Low |
Intervention NR Function · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Foot alignment · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | 3 studies · 4 participants | Ungraded |
Intervention NR Gait assessment · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Time from randomisation until recovery of unaided walking, (median, days (95% CI)) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Time from randomisation until discontinuation of ventilation (for those ventilated) (median, weeks (range)) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 5 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Death · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 0.67 [0.06, 7.85] | 1 study · 10 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.33 [0.17, 10.25] | 1 study · 10 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Participants with 1 or more serious adverse events · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1 [0.28, 3.54] | 1 study · 10 participants | Very low |
Cerebrospinal fluid filtration vs plasma exchange Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Cerebrospinal fluid filtration vs plasma exchange Improvement in disability grade Defined as achievement of a specified degree of improvement · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 0.94 [0.48, 1.84] | 1 study · 37 participants | Very low |
Cerebrospinal fluid filtration vs plasma exchange Time from randomisation until recovery of unaided walking (median, days (range)) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 37 participants | Very low |
Cerebrospinal fluid filtration vs plasma exchange Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Cerebrospinal fluid filtration vs plasma exchange Death · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.18 [0.08, 17.42] | 1 study · 37 participants | Low |
Interferon beta‐1a vs placebo Improvement in disability grade Defined as achievement of a specified degree of improvement · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.08 [0.42, 2.77] | 1 study · 19 participants | Very low |
Cerebrospinal fluid filtration vs plasma exchange Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Cerebrospinal fluid filtration vs plasma exchange Participants with 1 or more serious adverse events · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 0.13 [0.01, 2.25] | 1 study · 37 participants | Very low |
Tripterygium polyglycoside vs corticosteroids Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Improvement in disability grade Defined as achievement of a specified degree of improvement · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.47 [1.02, 2.11] | 1 study · 43 participants | Very low |
Tripterygium polyglycoside vs corticosteroids Time from randomisation until recovery of unaided walking · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Death · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 43 participants | Ungraded |
Tripterygium polyglycoside vs corticosteroids Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Participants with 1 or more serious adverse events · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 43 participants | Ungraded |
Eculizumab vs placebo Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 2 studies · 40 participants | Very low |
Interferon beta‐1a vs placebo Time from randomisation until recovery of unaided walking (median, days (95% CI)) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
Eculizumab vs placebo Improvement in disability grade Defined as achievement of a specified degree of improvement · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 0.85 [0.43, 1.69] | 2 studies · 40 participants | Low |
Eculizumab vs placebo Time from randomisation until recovery of unaided walking (mean, weeks) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 7 participants | Low |
Eculizumab vs placebo Time from randomisation until discontinuation of ventilation (for those ventilated) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 2 studies · 8 participants | Very low |
Eculizumab vs placebo Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.5 [0.08, 26.86] | 2 studies · 38 participants | Low |
Eculizumab vs placebo Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.21 [0.15, 10.11] | 2 studies · 38 participants | Very low |
Eculizumab vs placebo Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.9 [0.34, 10.5] | 2 studies · 41 participants | Low |
Interferon beta‐1a vs placebo Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Death · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 1.5 [0.07, 32.29] | 1 study · 19 participants | Low |
Interferon beta‐1a vs placebo Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Participants with 1 or more serious adverse events · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | RR 0.92 [0.23, 3.72] | 1 study · 19 participants | Very low |
Brain‐derived neurotrophic factor vs placebo Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |